Retrospective Study
Copyright ©The Author(s) 2021.
World J Cardiol. Sep 26, 2021; 13(9): 493-502
Published online Sep 26, 2021. doi: 10.4330/wjc.v13.i9.493
Table 1 Patient characteristics
Characteristic
n = 35
Men29 (83%)
Age (mean ± SD)69 ± 12 yr
Hypertension33 (94%)
Hyperlipidemia25 (71%)
Diabetes14 (40%)
Smoking14 (40%)
Renal insufficiency14 (40%)
History of CHF6 (17%)
Prior MI20 (57%)
Ejection fraction (mean ± SD)43% ± 12%
Clinical presentation
STEMI6 (17%)
NSTEMI14 (40%)
Unstable angina14 (40%)
Stable angina1 (3%)
Canadian heart class
I, II0
III7 (20%)
IV28 (80%)
Table 2 Bypass graft characteristics
Characteristic
n (%)
SVG age (mean ± SD)12.1 ± 5.1 yr
Prior PCI of SVG10 (29)
Grafted native vessel
LAD9 (26)
LCx13 (37)
RCA10 (29)
Multiple3 (9)
Duration of graft occlusion
Acute (< 24 h)12 (34)
Subacute (> 24 h to 30 d)9 (26)
Late (> 30 d)14 (40)
Table 3 Procedural features and outcomes
Feature
n (%)
Anticoagulation
Heparin only12 (34)
Bivalirudin8 (23)
Heparin + GP IIb IIIa inhibitor15 (43)
Thrombectomy20 (57)
Distal protection device9 (26)
Number of stents (mean ± SD)2.1 ± 1.3
Total stent length (mean ± SD)52 ± 35 mm
Stent type
Drug-eluting19 (55)
Bare metal11 (31)
None5 (14)
Procedural outcome
Success29 (83)
Failed6 (17)
Procedural complications
Distal embolization1 (3)
No reflow5 (15)
In-hospital MACE
Death2 (5.7)
Myocardial infarction1 (2.9)
Stroke0
Repeat PCI or CABG0
Any MACE3 (8.6)
Table 4 Follow-up major adverse cardiac event
MACE type
n (%)
Death5 (14)
Stroke1 (3)
MI15 (43)
Repeat bypass surgery0
Repeat PCI6 (17)
Graft reocclusionAny MACE7 (20) 28 (80)